Neurocrine Biosciences' positive phase 2 trial results for a schizophrenia treatment fell short compared to competitors like Bristol Myers Squibb. Despite this setback, an expanded final-stage trial is planned, bringing the industry closer to a new treatment for schizophrenia after 70 years.